Cellectis S.A. Files Form 6-K with April 8 Press Release

Ticker: CLLS · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1627281

Sentiment: neutral

Topics: reporting, foreign-private-issuer

Related Tickers: CLLS

TL;DR

Cellectis (CLLS) filed a 6-K on 4/8, including a press release. Stay tuned for updates.

AI Summary

Cellectis S.A. filed a Form 6-K on April 8, 2024, reporting information for the month of April 2024. The filing includes a press release dated April 8, 2024, as Exhibit 99.1. Cellectis S.A. is a foreign private issuer based in Paris, France, and files annual reports under Form 20-F.

Why It Matters

This filing indicates ongoing reporting activity for Cellectis S.A., providing investors with updated information through a press release.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the issuer makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

What specific exhibit is included with this 6-K filing?

This 6-K filing includes Exhibit 99.1, which is a Press Release dated April 8, 2024.

Does Cellectis S.A. file annual reports under Form 20-F or 40-F?

Cellectis S.A. indicates that it files annual reports under cover of Form 20-F.

Where is Cellectis S.A. headquartered?

Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.

What is the Commission File Number for Cellectis S.A.'s filings?

The Commission File Number for Cellectis S.A. is 001-36891.

Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-04-08 16:35:07

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: April 8, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing